Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.51
-0.1800-4.88%
Post-market: 3.50-0.0100-0.28%19:59 EDT
Volume:8.49M
Turnover:30.53M
Market Cap:1.45B
PE:-3.21
High:3.72
Open:3.66
Low:3.51
Close:3.69
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:0.68
T/O Rate:2.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:2.07
PE(LYR):-3.21

Loading ...

Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut

Stock Track
·
Nov 07, 2025

Chardan Cuts Price Target on Iovance Biotherapeutics to $17 From $20, Keeps Buy Rating

MT Newswires Live
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 07, 2025

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 07, 2025

Iovance Biotherapeutics Up Over 35%, on Pace for Largest Percent Increase Since May 2019 -- Data Talk

Dow Jones
·
Nov 07, 2025

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress

Stock Track
·
Nov 06, 2025

Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation

Reuters
·
Nov 06, 2025

Stock Track | Iovance Biotherapeutics (IOVA) Surges 13.82% Pre-market on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 06, 2025

Stock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 06, 2025

Iovance Biotherapeutics Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $67.455M Miss $72.402M Estimate

Benzinga
·
Nov 06, 2025

Iovance Biotherapeutics Reports 13% Revenue Growth and Improved Gross Margin in Q3 2025

Reuters
·
Nov 06, 2025

Iovance Biotherapeutics Inc: Full-Year 2025 Revenue Guidance Is Reaffirmed

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Q3 EPS USD -0.25 VS. Ibes Estimate USD -0.25

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Q3 Revenue USD 68 Million

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

GlobeNewswire
·
Nov 06, 2025

Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug

Dow Jones
·
Nov 03, 2025

Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial

Reuters
·
Nov 03, 2025

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel Til Cell Therapy in Advanced Non-Small Cell Lung Cancer (Nsclc)

THOMSON REUTERS
·
Nov 03, 2025

Iovance Biotherapeutics Inc: Iov-Lun-202 Trial to Advance in 2026 Toward Lifileucel Bla in Nonsquamous Nsclc

THOMSON REUTERS
·
Nov 03, 2025